FDA Clears Way for Phase 1 Trial of Low-dose Oral Carbon Monoxide

FDA Clears Way for Phase 1 Trial of Low-dose Oral Carbon Monoxide

293243

FDA Clears Way for Phase 1 Trial of Low-dose Oral Carbon Monoxide

The U.S. Food and Drug Administration has cleared the way for a Phase 1 trial of HBI-002, Hillhurst Biopharmaceuticals‘ oral carbon monoxide treatment for sickle cell disease (SCD). The trial will assess the safety, tolerability, and pharmacokinetics (how the therapy moves through the body) of single and multiple doses of the compound in healthy subjects. The study is expected to begin mid-year. “We are very pleased that Hillhurst’s first [investigational new drug application] has been…

You must be logged in to read/download the full post.